These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pegylated interferons for the treatment of chronic hepatitis C infection. Luxon BA; Grace M; Brassard D; Bordens R Clin Ther; 2002 Sep; 24(9):1363-83. PubMed ID: 12380630 [TBL] [Abstract][Full Text] [Related]
4. Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Perry CM; Jarvis B Drugs; 2001; 61(15):2263-88. PubMed ID: 11772139 [TBL] [Abstract][Full Text] [Related]
5. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles. Bruno R; Sacchi P; Cima S; Maiocchi L; Novati S; Filice G; Fagiuoli S J Viral Hepat; 2012 Jan; 19 Suppl 1():33-6. PubMed ID: 22233411 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study. Brennan BJ; Xu ZX; Grippo JF Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176 [TBL] [Abstract][Full Text] [Related]
7. Pegylated interferon monotherapy for chronic hepatitis C. Heathcote J; Zeuzem S Semin Liver Dis; 2004; 24 Suppl 2():39-45. PubMed ID: 15346245 [TBL] [Abstract][Full Text] [Related]
8. Population PK-PD Model of Pegylated Interferon Alfa-2a in Healthy Korean Men. Jung YS; Chae D; Park K J Pharm Sci; 2018 Dec; 107(12):3171-3178. PubMed ID: 30179597 [TBL] [Abstract][Full Text] [Related]
9. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. McHutchison J; Sulkowski M J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672 [TBL] [Abstract][Full Text] [Related]
10. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079 [TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus. Foster GR Expert Opin Pharmacother; 2003 May; 4(5):685-91. PubMed ID: 12739994 [TBL] [Abstract][Full Text] [Related]
12. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Nieforth KA; Nadeau R; Patel IH; Mould D Clin Pharmacol Ther; 1996 Jun; 59(6):636-46. PubMed ID: 8681488 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346 [TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects. Zheng L; Li MP; Gou ZP; Wang Y; Xu N; Cai YM; Luo H Br J Clin Pharmacol; 2015 Apr; 79(4):650-9. PubMed ID: 25297637 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760 [TBL] [Abstract][Full Text] [Related]
16. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Zeuzem S; Heathcote JE; Martin N; Nieforth K; Modi M Expert Opin Investig Drugs; 2001 Dec; 10(12):2201-13. PubMed ID: 11772316 [TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Brennan BJ; Morcos PN; Wang K; Blotner SD; Morrison R; Hagedorn CH; Marbury TC; Sulkowski M; Grippo JF Aliment Pharmacol Ther; 2012 May; 35(10):1209-20. PubMed ID: 22469033 [TBL] [Abstract][Full Text] [Related]
18. Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C. Ferenci P Int J Clin Pract; 2003 Sep; 57(7):610-5. PubMed ID: 14529063 [TBL] [Abstract][Full Text] [Related]
19. Comparative study concerning the efficacy of Peg-IFN alpha-2a versus Peg-IFN alpha-2b on the early virological response (EVR) in patients with chronic viral C hepatitis. Sporea I; Danila M; Sirli R; Popescu A; Laza A; Baditoiu L J Gastrointestin Liver Dis; 2006 Jun; 15(2):125-30. PubMed ID: 16802006 [TBL] [Abstract][Full Text] [Related]